Background: Chronic kidney disease (CKD), being a progressive disorder, is associated with the gradual deterioration of kidney function and involves complex metabolic disturbances. The identification of reliable circulating markers may help in the assessment of the severity of renal dysfunction.
Aim of study: To assess the circulating levels of Meteorin-Like protein (METRNL) and Fibroblast Growth Factor-21 (FGF-21), as well as ascertain the the diagnostic value and correlation with the parameters of renal function in chronic kidney disease patients.
Materials and Methods: This study was a case-control study, and a total of 90 subjects were included in the study, out of which 60 were patients with CKD and 30 were healthy controls. The patients with CKD were divided into mild to moderate and advanced stages of CKD. The serum levels of METRNL and FGF-21 were measured by the ELISA method, and the levels of serum creatinine, blood urea, and eGFR were measured.
Results: There was a significant decrease in the serum levels of METRNL in patients with CKD compared to the control subjects. The serum levels of METRNL in patients with CKD were 245.7 ± 71.3 and 182.6 ± 64.9 pg/mL, compared to 312.4 ± 85.6 pg/mL in the control subjects. The results showed that there was a significant increase in the serum levels of FGF-21 in patients with CKD compared to the control subjects. The serum levels of FGF-21 in patients with CKD were 214.9 ± 62.8 and 356.2 ± 95.4 pg/mL, compared to 108.5 ± 36.7 pg/mL in con